Drugs / apricoxib
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00569114 | Oct 2007 → Apr 2009 | non-small cell lung carcinoma | Tragara Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05841550 | May 2023 → May 2027 expected | smoldering plasma cell myeloma | Oslo University Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02261714 | Dec 2012 → May 2019 | pancreatic adenocarcinoma | Targovax ASA | Completed | No outcome recorded |
| Phase 25 trials · 2 missed | ||||||
| Phase 2 | NCT05638698 | Dec 2022 → Dec 2024 overdue | neoplasm | University of Kansas Medical Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT00771953 | Nov 2008 → May 2012 | non-small cell lung carcinoma | University of Maryland, Baltimore | Completed | Missed primary |
| Phase 2 | NCT00709826 | Aug 2008 → Jun 2010 | malignant pancreatic neoplasm | Tragara Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00657137 | Apr 2008 → Sep 2009 | breast cancer | Tragara Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00652340 | Apr 2008 → Jun 2010 | non-small cell lung carcinoma | Tragara Pharmaceuticals, Inc. | Completed | Missed primary |
| Phase not applicable1 trial | ||||||
| — | NCT01532362 | Nov 2011 → May 2012 | non-small cell lung carcinoma | Jonsson Comprehensive Cancer Center | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 22
| Date | Issuer | Release |
|---|---|---|
| 2025-06-16 | Targovax Oy | Results TG01 mutant RAS cancer vaccine data showing clinical benefit in multiple myeloma presented at EHA 2025 circio.com ↗
TG01 vaccination led to an increase in mutant RAS T-cells in 6 patients; 5 of these patients remain on study with stable disease |
| 2024-03-04 | Targovax Oy | Regulatory The TG01 IND application by Circio’s partner IOVaxis Therapeutics has been approved by the Chinese regulatory authorities circio.com ↗
The IND application filed by partner IOVaxis Therapeutics to initiate TG01 clinical development in China was approved by the Chinese NMPA on 1 March 2024 |
| 2023-12-12 | Targovax Oy | Regulatory TG01 IND application filed in China by Circio’s partner IOVaxis Therapeutics circio.com ↗
Circio Holding ASA (OSE: CRNA ) announces that partner IOVaxis Therapeutics of Nantong, China, has filed the updated TG01 investigational new drug (IND) application with the Chinese National Medical Products Administration (NMPA), with an expected review period of sixty days. |
| 2023-12-07 | Targovax Oy | Results Circio announces completion of planned safety review and opening for full enrollment of TG01 study at Oslo University Hospital circio.com ↗
today announces that mutant RAS cancer vaccine TG01 adjuvanted by QS-21 STIMULON has passed the planned safety cohort review without any concerns in the multiple myeloma trial at Oslo University Hospital (OUS). |
| 2022-12-22 | Targovax Oy | Regulatory Targovax announces that the TG01 study in multiple myeloma at Oslo University Hospital has received regulatory approvals to proceed circio.com ↗
The Norwegian Medicines Agency (NOMA) and the Regional Ethics Committee (REK) have today approved the clinical trial application for TG01 in multiple myeloma |
| 2022-12-15 | Targovax Oy | Regulatory Targovax announces clinical trial collaboration with Agenus to test TG mutant RAS vaccination in pancreatic cancer circio.com ↗
The trial has been given approval to proceed by the US Food and Drug Administration (FDA), and will be activated on December 15 |
| 2022-06-23 | Targovax Oy | Regulatory Targovax: FDA gir tillatelse til å starte kliniske studier med ny og forbedret TG01 kreftvaksine i USA circio.com ↗
Targovax ASA (OSE: TRVX) melder i dag at en «legemiddel under utvikling» (IND) søknad for TG01 i kombinasjon med QS-21 STIMULON har blitt godkjent av det amerikanske FDA. |
| 2022-06-23 | Targovax Oy | Regulatory Targovax: FDA gir tillatelse til å starte kliniske studier med ny og forbedret TG01 kreftvaksine i USA circio.com ↗
Targovax ASA (OSE: TRVX) melder i dag at en «legemiddel under utvikling» (IND) søknad for TG01 i kombinasjon med QS-21 STIMULON har blitt godkjent av det amerikanske FDA. |
| 2022-06-23 | Targovax Oy | Regulatory Targovax announces that the FDA has granted authorization to initiate clinical trials with the enhanced TG01 RAS vaccine in the USA circio.com ↗
The US Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) Application for the combination of TG01 and QS-21 STIMULON™ |
| 2019-05-23 | Targovax Oy | Results Targovax announces median and three-year overall survival for TG01 trial in resected pancreatic cancer circio.com ↗
Oslo, Norway, 23 May 2019 – Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces median overall survival of 33.3 months and 38% three-year survival rate in the 32-patient phase I/II clinical trial evaluating TG01 in resected pancreatic cancer in combination with standard of care chemotherapy (gemcitabine) . |
| 2018-10-15 | Targovax Oy | Results Targovax reports encouraging disease-free survival (DFS) data from TG01 trial in resected pancreatic cancer circio.com ↗
Median DFS for all 32 patients in the trial was 16.1 months, and 19.5 months for the 2nd patient cohort who received an optimized dosing regimen. |
| 2018-05-24 | Targovax Oy | Results Targovax strengthens 2-year survival rate in resected pancreatic cancer with TG01 circio.com ↗
Median overall survival (mOS) for all 32 patients was 33.4 months, which is nearly six months better than the mOS of 27.6 months for gemcitabine alone reported in the recent ESPAC4 trial(1). |
| 2017-10-12 | Targovax Oy | Results Targovax announces one-year survival rate and safety data in the modified cohort of the TG01 trial in resected pancreatic cancer circio.com ↗
Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces one-year data on survival rate, immune activation and safety in the modified cohort of the TG01 trial in resected pancreatic cancer patients. |
| 2017-09-11 | Targovax Oy | Results Targovax ASA: Three posters presented at ESMO conference circio.com ↗
The two posters summarizing the encouraging data from early clinical studies with TG01, from the neo-antigen therapeutic cancer vaccine platform, suggest it may have significant potential in the treatment of RAS-mutated pancreatic cancer, which currently has a poor prognosis. |
| 2017-06-06 | Targovax Oy | Results Targovax presents further positive clinical data from TG01 phase I/II trial at 2017 ASCO annual meeting circio.com ↗
The data show that: TG01/GM-CSF generated early immune responses in 89% of patients (17/19) with resected pancreatic cancer. |
| 2017-02-02 | Targovax Oy | Results Targovax announces encouraging top line two-year survival data from TG01 clinical trial in resected pancreatic cancer patients circio.com ↗
We are encouraged by the two-year overall survival rate of patients treated with TG01 in this trial, versus the expected rate from published historical data when treating with gemcitabine alone, the current standard of care. |
| 2016-04-14 | Targovax Oy | Results Targovax reports immune response with reduced number of TG01 vaccinations circio.com ↗
The results show that the modified and reduced vaccination schedule generated similar 8-week immune responses in patients with pancreatic cancer, as seen in the initial cohort. |
| 2016-03-11 | Targovax Oy | Results Targovax in Dagens Medisin circio.com ↗
Targovax’s Chair of the Board, Jonás Einarsson, is interviewed by Dagens Medisin regarding promising 1-year overall survival data when combining TG01 with gemcitabine (chemotherapy) as supplementary treatment of patients with pancreatic cancer. |
| 2016-03-10 | Targovax Oy | Results Targovax announces encouraging interim results with RAS specific peptide vaccine in resected pancreatic cancer circio.com ↗
Targovax has conducted a predetermined interim analysis of the TG01 Phase I/II trial, indicating promising 1-year overall survival data when combining TG01 with gemcitabine (chemotherapy) as supplementary treatment of patients with pancreatic cancer. |
| 2015-06-01 | Targovax Oy | Results Targovax presented safety data and immunological results at the 2015 ASCO Annual Meeting circio.com ↗
The preliminary results from the study indicate that about 80% or more of the patients mount an immune response to TG01. |
| 2014-11-03 | Targovax Oy | Results Targovax AS has reached an important milestone circio.com ↗
Targovax meddeler at primært endepunkt for pågående fase I/II studie CT TG01-01, vedrørende immunrespons og bivirkninger, allerede er nådd. |
| 2012-11-01 | Targovax Oy | Regulatory TG01 getting ready for phase I/II circio.com ↗
The application for clinical trials, CTA, was submitted to the Norwegian Medicines Agency in August. |
All press releases naming this drug 40 releases
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Apricoxib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01532362 ↗ |
| Known as | CS-706 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1835207 ↗ |
| Known as | R-109339 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1835207 ↗ |
| Known as | TG01 | “Drug: TG01” NCT00569114 ↗ |
| Action | Inhibit | “apricoxib, a novel COX-2 inhibitor” PMID 24736085 ↗ Apr 20141“Cyclooxygenase-2 inhibitor” CHEMBL1835207 ↗ |
| Modality | Small molecule | — CHEMBL1835207 ↗ |
| Modality | Vaccine | “TG01 vaccine” NCT05638698 ↗ |
| Route | Oral | “given orally” NCT00569114 ↗ |
| Target | PTGS2 | “Cyclooxygenase-2 inhibitor” CHEMBL1835207 ↗ |